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ABSTRACT
We describe the design and detailed characterization
of 6-hydroxy-nicotine (6HNic)-adjustable transgene
expression (NICE) systems engineered for lentiviral
transduction and in vivo modulation of angiogenic
responses. Arthrobacter nicotinovorans pAO1
encodes a unique catabolic machinery on its plasmid
pAO1, which enables this Gram-positive soil bac-
terium to use the tobacco alkaloid nicotine as the
exclusive carbon source. The 6HNic-responsive
repressor-operator(HdnoR-ONIC)interaction,control-
ling 6HNic oxidase production in A.nicotinovorans
pAO1, was engineered for generic 6HNic-adjustable
transgene expression in mammalian cells. HdnoR
fused to different transactivation domains retained
its ONIC-binding capacity in mammalian cells and
reversibly adjusted transgene transcription from chi-
meric ONIC-containing promoters (PNIC;O NIC fused to
a minimal eukaryotic promoter [Pmin]) in a 6HNic-
responsive manner. The combination of transact-
ivators containing various transactivation domains
with promoters differing in the number of operator
modules as well as in their relative inter-ONIC and/or
ONIC-Pminspacingrevealedstericconstraintsinfluen-
cing overall NICE regulation performance in mamma-
lian cells. Mice implanted with microencapsulated
cells engineered for NICE-controlled expression of
the human glycoprotein secreted placental alkaline
phosphatase(SEAP)showedhighSEAPserumlevels
in the absence of regulating 6HNic. 6HNic was
unable to modulate SEAP expression, suggesting
that this nicotine derivative exhibits control-
incompatible pharmacokinetics in mice. However,
chicken embryos transduced with HIV-1-derived
self-inactivating lentiviral particles transgenic for
NICE-adjustable expression of the human vascular
endothelial growth factor 121 (VEGF121) showed
graded 6HNic response following administration of
different6HNicconcentrations.Owingtotheclinically
inertandhighlywater-solublecompound6HNic,NICE-
adjustable transgene control systems may become
a welcome alternative to available drug-responsive
homologs in basic research, therapeutic cell engine-
ering and biopharmaceutical manufacturing.
INTRODUCTION
TheGram-positivesoilbacteriumArthrobacternicotinovorans
pAO1 acquired the metabolic capacity to metabolize the
tobacco alkaloid nicotine as an exclusive carbon source.
Utilization is initiated by hydroxylation of nicotine’s pyridine
ring at position C6 followed by oxidation mediated by the
6-hydroxy-nicotine oxidase (6HNO). Recent sequence ana-
lysis of the catabolic plasmid pAO1 revealed the 6HNO gene
repressor HdnoR, which controls 6HNO expression in the
presence of 6-hydroxy-nicotine (6HNic) (1). 6HNic modulates
HdnoR’s allosteric conformation in a way that prevents further
binding and repression of the 6HNO promoter, thereby res-
ulting in induction of follow-up nicotine-speciﬁc metabolic
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doi:10.1093/nar/gni107pathways. 6HNic produced by A.nicotinovorans pAO1 came
into the limelight as a bio-catalytic bulk product, which can be
employed in conventional esteriﬁcation processes or as an
educt for the production of particular special chemicals,
including 6-alkoxynicotine derivatives known to exhibit anti-
bacterial and antifungal activities (2). In addition to being an
intermediate product in (bio-) chemical production scenarios,
6HNic is also a by-product of pioneering efforts to denicot-
inize tobacco for the production of ‘mild’ or ‘light’ cigarettes
characterized by a low nicotine content (3,4). Besides its
involvement in the aforementioned processes, knowledge of
6HNic’s physiologic impact and pharmacokinetics is limited
or non-existing. However, unlike nicotine itself, 6HNic is
expected to be more soluble and unable to trigger nicotine-
speciﬁc receptor responses because of its hydroxylated
aromatic ring (5).
HdnoR has been reported to belong to the TetR family of
bacterial response regulators, which repress target genes in a
physiologic compound-responsive manner (1). In particular,
TetR dissociates from a cognate PTetA promoter in the pres-
ence of tetracycline antibiotics and so induces the expression
of the tetracycline resistance gene tetA (6). Pioneering efforts
in using bacterial response regulators for mammalian trans-
gene expression ﬁne-tuning have resulted in the design
of the tetracycline-responsive expression system [the TET
system(s)], which consists of its generic conﬁguration of
TetR fused to a Herpes simplex-derived VP16 transactivation
domain (tTA) and a heptameric TetR-speciﬁc tetA promoter-
derived operator module (tetO7) functionally linked to the
minimal version of the human cytomegalovirus immediate
early promoter (tetO7-PhCMVmin;P hCMV* 1). tTA binding
to PhCMV* 1 induced desired transgene transcription in the
absence of tetracycline. However, tetracycline switched
tTA’s allosteric conformation to a PhCMV* 1 binding-
incompetent state, which resulted in dose-dependent transgene
repression (7).
Following the generic design principle of the TET system,
a wide variety of bacterial response regulators have been
adapted for use as mammalian gene regulation systems,
including those responsive to (i) tetracycline derivatives
(7,8), (ii) streptogramin (9), (iii) macrolide (10) and (iv) cou-
mermycin (11) antibiotics, (v) immunosuppressive rapamycin
(12), hormones such as (vi) estrogen (13), (vii) progesterone
(14)and(viii)ecdysone(15),(ix)temperature(16),(x)quorum-
sensing molecules (17,18), (xi) the terpene cumate (http://
www.qbiogene.com/products/gene-expression/qmateslideshow/
index.htm), (xii) the type-2 diabetes drug roziglitazone (19)
and (xiii) gaseous acetaldehyde (20).
Most transgene regulation modalities were conceived
or have been used as stand-alone systems [one-gene control
system modulating a single (set of) transgene(s)] for targeted
molecular interventions in complex regulatory networks,
including (i) prototype gene therapy and tissue engineering
scenarios (12,21), (ii) drug discovery (22,23), (iii) biopharma-
ceutical manufacturing (24,25) and (iv) gene-function analysis
(26). Clinically licensed antibiotics (macrolide, streptogramin,
coumermycin and tetracycline), immunosuppressive agents
(rapamycin), hormones (mifepristone) and PPAR-g (peroxi-
some proliferator-activated receptor-g) agonists (roziglit-
azone) seem to be ideal candidates for gene therapy-based
conditional transgene interventions. However, some of these
drugs may elicit side effects following long-term admini-
stration at regulation-effective concentrations (27–29). Fur-
thermore, drug-based inducers are less suited for transgene
modulation of biotechnologically relevant production cell
lines, since preparation of inducer-free product formulations
remains a costly downstream processing challenge.
Availability of different compatible transgene regulation
systems enabled their functional interconnection to produce
synthetic mammalian networks with unprecedented signal
integration. The most prominent mammalian cell-embedded
synthetic regulatory networks include: (i) an artiﬁcial regu-
latory cascade consisting of three heterologous transcription
control units interconnected in a linear manner to produce
discrete multilevel expression control of a terminally encoded
transgene in response to clinical doses of different antibiotics
(30), (ii) an epigenetic circuitry able to switch between
two stable transgene expression states after transient admin-
istration of two alternate drugs (31) and BioLogic gates pro-
viding transgene expression integration reminiscent of digital
electronics (32).
We have designed a novel gene regulation system [6HNic-
adjustabletransgeneexpression(NICE)]responsivetothenon-
toxic nicotine derivative 6HNic. NICE technology enabled
ﬁne-tuning of transgene expression in mammalian cells,
was compatible with state-of-the-art lentiviral transduction
and provided precise control of angiogenic responses in
chicken embryos. Since NICE systems are responsive to a
clinically inert, highly water-soluble nicotine derivative, we
believe it will foster advances in basic research as well as in
biopharmaceutical manufacturing.
MATERIALS AND METHODS
Plasmid construction
All plasmids used in this study are listed in Table 1; detailed
information on their construction is also provided.
Cell culture and transfection
Chinese hamster ovary cells (CHO-K1, ATCC CCL 61) were
cultivated in standard medium: FMX-8 medium (Cell Culture
Technologies, Zurich, Switzerland) supplemented with 10%
fetal calf serum (FCS) (Pan Biotech GmbH, Aidenbach,
Germany; catalog no. 3302-P231902, lot no. P231902).
Human embryonic kidney cells transgenic for simian virus
40 (SV40) large T antigen [HEK293-T (33)] were cultivated
in DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% FCS. All cell lines were cultivated at 37 Ci na5 %
CO2-containing humidiﬁed atmosphere. CHO-K1 cells were
transfected using an optimized calcium phosphate-based
protocol that resulted in standard transfection efﬁciencies of
35 – 5%. In brief, 40 000 CHO-K1 cells were seeded per well
of a 24-well plate and cultivated overnight. Aliquots contain-
ing 6 mg of plasmid DNA (for cotransfections equal amounts
of each plasmid were used) were diluted in 60 ml of 250 mM
CaCl2 and precipitated following drop-wise addition of 60 ml
phosphate solution for 20 s (50 mM HEPES, 280 mM NaCl,
1.5 mM Na2HPO4, pH 7.1). Following further incubation for
10 s, 2 ml FMX-8 containing 2% FCS were added. The culture
medium was replaced by the DNA-precipitate-containing
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Plasmid Description and cloning strategy Reference or
source
pBM57 HIV-1-derived lentiviral expression vector (50LTR-y
+-oriSV40-cPPT-RRE-EYFP-30LTRDU3) (33)
pBM104 Lentiviral expression vector encoding a PPIR8-driven VEGF121 expression unit
(50LTR-y
+-oriSV40-cPPT-RRE-PPIR8-VEGF121-30LTRDU3)
(68)
pBM105 Lentiviral expression vector encoding a PPIR8-driven SEAP expression unit
(50LTR-y
+-oriSV40-cPPT-RRE-PPIR8-VEGF121-30LTRDU3)
(68)
pBP10 Vector encoding a PETR5-driven SEAP expression unit (PETR5-SEAP-pA; PETR5, ETR-2bp-PhCMVmin) (47)
pBP11 Vector encoding a PETR6-driven SEAP expression unit (PETR6-SEAP-pA; PETR6, ETR-4bp-PhCMVmin) (47)
pBP12 Vector encoding a PETR7-driven SEAP expression unit (PETR7-SEAP-pA; PETR7, ETR-6bp-PhCMVmin) (47)
pBP13 Vector encoding a PETR8-driven SEAP expression unit (PETR8-SEAP-pA; PETR8, ETR-8bp-PhCMVmin) (47)
pBP14 Vector encoding a PETR9-driven SEAP expression unit (PETR9-SEAP-pA; PETR9, ETR-10bp-PhCMVmin) (47)
pH6EX3-HdnoR Vector encoding the A.nicotinovorans pAO16 repressor of the 6HNic oxidase (HdnoR) (1)
pLM82 Constitutive NT1 expression vector (PSV40-NT1-pA; NT1, HdnoR-VP16) This work
HdnoR was PCR-amplified from pH6EX3-HdnoR using OLM83: 5-GTACgaattcCCACCatgcgtatttccacggtggatcg-30
and OLM84: 50-CTTATGgcgcgcGGCTGTACGCGGAtagtcctacccgatcgaggta-30 (lower case, annealing sequence;
lower case italics, restriction sites), restricted with EcoRI/BssHII and ligated into the corresponding sites
(EcoRI/BssHII) of pWW35
pLM83 Vector encoding a PNIC1a-driven SEAP expression unit (PNIC1a-SEAP-pA; PNIC1a,O NIC-0bp-PhCMVmin) This work
PhCMVmin was PCR-amplified from pRevTRE using OLM82: 50-GATCgacgtcCCCCATTGACATGGACAGCTGTC-
CATGTATCAATAGGGTGcctgcaggtcgagctcggtacccgggtc-30 and OWW22:
50-GCTAgaattccgcggaggctggatcgg-30 (lower case, annealing sequence; lower case italics, restriction sites;
upper case, ONIC), restricted with AatII/EcoRI and ligated into the corresponding sites (AatII/EcoRI) of pMF111
pLM101 Constitutive NT2 expression vector (PSV40-NT2-pA; NT2, HdnoR-p65) This work
The NF-kB-derived transactivation domain (p65) was excised from pWW42 using BssHII/BamHI and ligated into the
corresponding sites (BssHII/BamHI) of pLM82
pLM102 Constitutive NT3 expression vector (PSV40-NT3-pA; NT3, HdnoR-E2F4) This work
The E2F4-derived transactivation domain (E2F4) was excised from pWW64 using BssHII/BamHI and ligated into the
corresponding sites (BssHII/BamHI) of pLM82
pLM103 Lentiviral NT1 expression vector (50LTR-y
+-oriSV40-cPPT-RRE-PhEF1a-NT1-30LTRDU3; NT1, HdnoR-VP16) This work
NT1 was excised from pLM82 using NotI/XmaI and ligated into the corresponding sites (NotI/XmaI) of pMF391
pLM104 Vector encoding a PNIC1b-driven SEAP expression unit (PNIC1b-SEAP-pA; PNIC1b,O NIC-2bp-PhCMVmin) This work
2bp-PhCMVmin-SEAP was excised from pBP10 using SbfI/XhoI and ligated into the corresponding sites
(SbfI/XhoI) of pLM83
pLM105 Vector encoding a PNIC1c-driven SEAP expression unit (PNIC1c-SEAP-pA; PNIC1c,O NIC-4bp-PhCMVmin) This work
4bp-PhCMVmin-SEAP was excised from pBP11 using SbfI/XhoI and ligated into the corresponding sites
(SbfI/XhoI) of pLM83
pLM106 Vector encoding a PNIC1d-driven SEAP expression unit (PNIC1d-SEAP-pA; PNIC1d,O NIC-6bp-PhCMVmin) This work
6bp-PhCMVmin-SEAP was excised from pBP12 using SbfI/XhoI and ligated into the corresponding
(SbfI/XhoI) sites of pLM83
pLM107 Vector encoding a PNIC1e-driven SEAP expression unit (PNIC1e-SEAP-pA; PNIC1e,O NIC-8bp-PhCMVmin) This work
8bp-PhCMVmin-SEAP was excised from pBP13 using SbfI/XhoI and ligated into the corresponding
(SbfI/XhoI) sites of pLM83
pLM108 Vector encoding a PNIC1f-driven SEAP expression unit (PNIC1f-SEAP-pA; PNIC1f,O NIC-10bp-PhCMVmin) This work
10bp-PhCMVmin-SEAP was excised from pBP14 using SbfI/XhoI and ligated into the corresponding
(SbfI/XhoI) sites of pLM83
pLM116 BamHI-AscI-StuI-AatII-XbaI-ONIC-0bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM90
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAA-
TAGGGTGTgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with (BamHI/ClaI) and ligated into the corresponding sites (BamHI/ClaI) of pWW139
(lower case, annealing sequence; lower case italics, restriction sites; upper case, ONIC)
This work
pLM118 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(XbaI/ClaI) of pLM116. PhEF1a-ONIC2-0bp-ONIC1-EPO-pA
This work
pLM119 AscI-StuI-AatII-XbaI-ONIC-2bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM91
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAAT-
AGGGTGATTgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with AscI/ClaI and ligated into the corresponding sites (AscI/ClaI) of pLM116.
PhEF1a-ONIC2-2bp-ONIC1-EPO-pA
This work
pLM120 AscI-StuI-AatII-XbaI-ONIC-4bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM92
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAA-
TAGGGTGATCGTgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with AscI/ClaI and ligated into the corresponding sites (AscI/ClaI) of pLM116.
PhEF1a-ONIC2-4bp-ONIC1-EPO-pA
This work
pLM121 AscI-StuI-AatII-XbaI-ONIC-6bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM93
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAAT-
AGGGTGATCGTATgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with AscI/ClaI and ligated into the corresponding sites (AscI/ClaI) of pLM116.
PhEF1a-ONIC2-6bp-ONIC1-EPO-pA
This work
pLM122 AscI-StuI-AatII-XbaI-ONIC-8bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM94
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAATAG-
GGTGATCGTAATTgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with AscI/ClaI and ligated into the corresponding sites (AscI/ClaI) of pLM116.
PhEF1a-ONIC2-8bp-ONIC1-EPO-pA
This work
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pLM123 AscI-StuI-AatII-XbaI-ONIC-10bp-NheI-SbfI-EcoRI-EPO was PCR-amplified from pWW139 using OLM95
50-CGggatccAggcgcgccAaggcctTTgacgtctctagaTACCCCATTGACATGGACAGCTGTCCATGTATCAATAGG-
GTGATCGTACGATTgctagcTTcctgcagggaattccaccatgg-30 and OWW51 50-gcgcgcatcgattcacctgtcccctctcctgcag-30,
restricted with AscI/ClaI and ligated into the corresponding sites (AscI/ClaI)
of pLM116. PhEF1a-ONIC2-10bp-ONIC1-EPO-pA
This work
pLM124 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(NheI/ClaI) of pLM119, thereby resulting in PhCMV-ONIC2-2bp-ONIC1-EPO-pA
This work
pLM125 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(NheI/ClaI) of pLM120, thereby resulting in PhCMV-ONIC2-4bp-ONIC1-EPO-pA
This work
pLM126 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(NheI/ClaI) of pLM121, thereby resulting in PhCMV-ONIC2-6bp-ONIC1-EPO-pA
This work
pLM127 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(NheI/ClaI) of pLM122, thereby resulting in PhCMV-ONIC2-8bp-ONIC1-EPO-pA
This work
pLM128 ONIC-NheI-SbfI-EcoRI-EPO was excised from pLM116 using XbaI/ClaI and ligated into the compatible sites
(NheI/ClaI) of pLM123, thereby resulting in PhCMV-ONIC2-10bp-ONIC1-EPO-pA
This work
pLM129 PhCMV-ONIC2-0bp-ONIC1-NheI was excised from pLM118 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-0bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM130 PhCMV-ONIC2-2bp-ONIC1 was excised from pLM124 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-2bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM131 PhCMV-ONIC2-4bp-ONIC1 was excised from pLM125 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-4bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM132 PhCMV-ONIC2-6bp-ONIC1 was excised from pLM126 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-6bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM133 PhCMV-ONIC2-8bp-ONIC1 was excised from pLM127 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-8bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM134 PhCMV-ONIC2-10bp-ONIC1 was excised from pLM128 using ScaI/SbfI and ligated into the corresponding sites
(ScaI/SbfI) of pLM105, thereby resulting in PhCMV-ONIC2-10bp-ONIC1-NheI-SbfI-4bp-PhCMVmin-SEAP-pA
This work
pLM135 Vector encoding a PNIC2a-driven SEAP expression unit (PNIC2a-SEAP-pA; PNIC2a,O NIC2-0bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM129 using AatII/AatII and the pLM129 backbone was self-ligated
This work
pLM136 Vector encoding a PNIC2b-driven SEAP expression unit (PNIC2b-SEAP-pA; PNIC2b,O NIC2-2bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM130 using AatII/AatII and the pLM130 backbone was self-ligated
This work
pLM137 Vector encoding a PNIC2c-driven SEAP expression unit (PNIC2c-SEAP-pA; PNIC2c,O NIC2-4bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM131 using AatII/AatII and the pLM131 backbone was self-ligated
This work
pLM138 Vector encoding a PNIC2d-driven SEAP expression unit (PNIC2d-SEAP-pA; PNIC2d,O NIC2-6bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM132 using AatII/AatII and the pLM132 backbone was self-ligated
This work
pLM139 Vector encoding a PNIC2e-driven SEAP expression unit (PNIC2e-SEAP-pA; PNIC2e,O NIC2-8bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM133 using AatII/AatII and the pLM133 backbone was self-ligated
This work
pLM140 Vector encoding a PNIC2f-driven SEAP expression unit (PNIC2f-SEAP-pA; PNIC2f,O NIC2-10bp-ONIC1-NheI-SbfI-4bp-
PhCMVmin). PhCMV was excised from pLM134 using AatII/AatII and the pLM134 backbone was self-ligated
This work
pLM141 PNIC2d (ONIC2-6bp-ONIC1-NheI-SbfI-4bp-PhCMVmin) was excised from pLM132 (AscI/EcoRI) and ligated into the
corresponding sites (AscI/EcoRI) of pBM105 (50LTR-y
+-oriSV40-cPPT-RRE-PNIC2d-SEAP-30LTRDU3;
PNIC2d,O NIC2-6bp-ONIC1-NheI-SbfI-4bp-PhCMVmin)
This work
pLM145 PhCMVmin-VEGF121 was excised from pBM104 using SbfI/SspI and ligated into the corresponding sites (SbfI/SspI)
of pLM120, thereby resulting in PNIC3-VEGF121-pA (PNIC3,O NIC-4bp-NheI-SbfI-PhCMVmin)
This work
pLM146 Lentiviral expression vector encoding a PNIC3-driven VEGF121 expression unit (50LTR-y
+-oriSV40-cPPT-RRE-PNIC3-
VEGF121-30LTRDU3;P NIC3,O NIC-4bp-NheI-SbfI-PhCMVmin). PNIC3–VEGF121 was excised from pLM145 using
AscI/MluI and ligated into the corresponding sites (AscI/MluI) of pBM104
This work
pMF111 Vector encoding a PhCMV* 1-driven SEAP expression unit (PhCMV* 1-SEAP-pA) (69)
pMF391 Lentiviral ET1 expression vector (50LTR-y
+-oriSV40-PPT-RRE- PhEF1a-ET1-30LTRDU3) (70)
pRevTRE Oncoretroviral expression vector containing a tetracycline-responsive expression unit Clontech,
Palo Alto, CA
Pseap2-Control Constitutive PSV40-driven SEAP expression vector Clontech,
Palo Alto, CA
pWW35 Constitutive ET1 expression vector (PSV40-ET1-pA) (10)
pWW42 Constitutive ET2 expression vector (PSV40-ET2-pA) (10)
pWW64 Constitutive ET4 expression vector (PSV40-ET4-pA) (10)
pWW139 EPO expression vector (18)
30LTRDU3, enhancer-free 30 long terminal repeat; 50LTR, 50 long terminal repeat; 6HNic, 6-hydroxy-nicotine; cPPT, central polypurine tract; E2F4, human
transcription factor, transactivation domain of the human E2F4; EPO, erythropoetin; ET1, macrolide-dependent transactivator (MphR(A)-VP16); ET2,
macrolide-dependent transactivator (MphR(A)-p65); ET4, macrolide-dependent transactivator (MphR(A)-E2F4); ETR, operator module specific for MphR(A);
EYFP, enhanced yellow fluorescent protein; HdnoR, repressor of the A.nicotinovorans pAO1 6HNic oxidase gene; MphR(A), E.coli-derived repressor of the
macrolide resistance genemphA; NF-kB, human transcription factor;NT1, 6HNic-dependent transactivator (HdnoR-VP16);NT2, 6HNic-dependent transactivator
(HdnoR-p65); NT3, 6HNic-dependent transactivator (HdnoR-E2F4); ONIC, HdnoR-specific operator; ONIC1/2,O NIC numbering in tandem operator configurations;
oriSV40, origin of replication of the SV40; p65, transactivation domain of NF-kB; pA; SV40-derived polyadenylation site; PETR2, macrolide-responsive promoter
(ETR-PhCMVmin);PETR5-9,macrolide-responsivepromoterscontainingdifferentspacersbetweenETRandPhCMVmin;P hCMV,promoterofthehumancytomegalovirus
immediateearlypromoter;PhCMVmin,minimalPhCMV;PhCMV* 1,tetracycline-responsivepromoter;PhEF1a,promoterofthehumanelongationfactor1alpha;PNIC1a-f,
6HNic-responsivepromoterscontainingdifferentspacersbetweenONICandPhCMVmin;P NIC2a-f,6HNic-responsivepromoterscontainingtandemONICoperatorswith
different inter-ONIC spacing but fixed spacing relative to PhCMVmin;P NIC3, 6HNic-responsive promoter with extended spacing between ONIC and PhCMVmin;P PIR8,
streptogramin-dependentpromoter;PSV40,constitutiveSV40promoter;RRE,revresponseelement;SEAP,humanplacentalsecretedalkalinephosphatase;VEGF121,
human vascular endothelial growth factor 121; VP16, H.simplex virus-derived transactivation domain; y
+, extended lentiviral packaging signal.
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(FMX-8 medium supplemented with 15% glycerol and 2%
FCS). After a single washing step using standard medium,
cells were cultivated for analysis in the presence or absence
of regulating 6HNic (50 mg/ml, unless stated otherwise).
Forty-eight hours post glycerol shock, reporter protein expres-
sion was proﬁled.
Lentiviral particle production and transduction
For production of replication-incompetent self-inactivating
HIV-1-derived lentiviral particles, HEK293-T cells were
co-transfected following an optimized calcium phosphate-
based protocol. In brief, 200 000 HEK293-T cells were seeded
per well of a 6-well plate and cultivated overnight in 2 ml 10%
FCS-containing DMEM. For each transfection, 1 mg pLTR-G
[encoding the pseudotyping envelope protein VSV-G of the
vesicular stomatitis virus (34)], 1 mg pCD/NL-BH* [helper
construct (35)] and 1 mg of the desired transgene-encoding
lentiviral expression vector were diluted in 100 ml of 250 mM
CaCl2. The DNA mixture was added drop-wise to 100 ml
phosphate solution (100 mM HEPES, 280 mM NaCl,
1.5 mM Na2HPO4, pH 7.1), incubated for 15 min to enable
formation of DNA-CaPO4 precipitates, which were sub-
sequently added to HEK293-T cultures. Five-hours post-
transfection, the DNA–CaPO4 complex was removed by
medium exchange and lentiviral particles were produced for
another 48 h prior to collection from the supernatant by
ﬁltration through a 0.45 mm ﬁlter (PIR8FP 030/2; Schleicher
& Schuell GmbH, Dassel, Germany). This protocol typically
yielded lentiviral particle titers of 2 · 10
7 c.f.u./ml following
titration on CHO-K1 cells or enzyme-linked immunosorbent
assay-based p24 quantiﬁcation according to the manufac-
turer’s protocol (catalog no. 103; Immunodiagnostics Inc.,
Woburn, MA). In order to prevent cross-contamination of
secreted proteins from production supernatants and increase
overall transduction efﬁciency, lentiviral particles were con-
centrated by ultracentrifugation for 2 h at 43 000 g and 4 C
(Beckman Quick-Seal centrifuge tubes; catalog no. 342413,
Beckman Instruments Inc., CA). The pellets were resuspended
in 10% FCS-containing DMEM to adjust viral concentrations
to desired levels. Furthermore, the culture medium was
exchanged 6 h post transduction to ensure that transgene
expression was exclusively based on transduction. Unless sta-
ted otherwise, standard transduction experiments included
infection of 24 000 target cells seeded per well of a 12-well
plate with 8 · 10
5 c.f.u. lentiviral particles (4 ng of p24).
Quantification of reporter protein production
Product proteins were quantiﬁed in cell culture supernatants
48 h after transduction. Human placental secreted alkaline
phosphatase (SEAP) production was assessed using a
chemiluminescence-based assay (Roche Diagnostics AG,
Rotkreuz, Switzerland). Human vascular endothelial growth
factor 121 (VEGF121) production was quantiﬁed using the
human VEGF-speciﬁc DuoSet ELISA System (R&D Systems,
Minneapolis, MO) according to the manufacturer’s protocol.
In vivo methods I—mice
CHO-K1 cells engineered for NICE-controlled SEAP expres-
sion by cotransfection of pLM82 (PSV40-NT1-pA) and
pLM104 (PNIC1b-SEAP-pA) were encapsulated in coherent
alginate-poly-(L-lysine)-alginate beads (200 cells/capsule,
2 · 10
6 cells/mouse) as described previously (10) and
implanted intraperitoneally into female OF1 mice (oncins
France souche 1; Iffa-Credo, Lyon, France). At 1 h after cap-
sule implantation, 6HNic was administered by intraperitoneal
injection at doses ranging from 0 to 100 mg/kg. 6HNic was
formulated for in vivo administration by dilution of stock
solutions to appropriate concentrations using physiological
salt solution [0.9% (w/v); Laboratoire Aguettant, Lyon,
France]. Control mice harbored encapsulated wild-type
CHO-K1 cells. At 72 h after 6HNic administration, the mice
were killed for blood collection and quantiﬁcation of SEAP
serumlevels usingmicrotainer SSTtubes (Beckton Dickinson,
Plymouth, UK) according to the manufacturer’s protocol. All
experiments involving mice were approved by the French
Ministry of Agriculture and Fishery (Paris, France) and
performed by M. D. El-Baba at the Institut Universitaire de
Technologie, IUTA, F-69622 Villeurbanne Cedex, France.
In vivo methods II—transduction of chicken embryos
The shell-free cultivation protocols of Djonov and co-workers
(36) were used for all experiments involving chicken embryos.
Brown Leghorn eggs were opened after 3 days incubation at
37 C and their contents were carefully poured into 80 mm
plastic Petri dishes. The chicken embryos were incubated
at 37 C in a humidiﬁed atmosphere. On embryonic day 9,
pLM146- (100 ml in DMEM, 8.5 · 10
6 c.f.u., 40 ng p24)
and pLM103- (90 ml in DMEM, 6.4 · 10
5 c.f.u., 3 ng p24)
derived lentiviral particles were co-applied locally on top of
the growing chorioallantoic membrane (CAM) together with
0.5 ml (0.5 nM in DMEM) CellTracker orange CMTMR (cata-
log no. C-2927; Molecular Probes Inc., Eugene, OR) to tag the
transduction site. In order to modulate heterologous VEGF121
expression, different concentrations of 6HNic (0, 0.1, 1 and
50 mg/ml) were administered 1 h post transduction. On embry-
onic day 12, the CAMs were examined by in vivo ﬂuorescence
microscopy following intravenous injection of 100 ml 2.5%
ﬂuoresceine isothiocyanate dextran (FITC) (2 000 000; Sigma
Chemicals, St Louis, MO) (37). FITC-stained CAM blood
vessels were visualized at 50· and 100· magniﬁcations using
a Leica DM-RB ﬂuorescence microscope equipped with a
Leica digital ﬂuorescence camera DC300 FX (Leica Micro-
systems AG, Heerbrugg, Switzerland) and a XF114 ﬁlter
(Omega Optical Inc., Brattleboro, VT).
HPLC-based quantification of 6-hydroxy-nicotine
6HNic concentrations in 2 ml mouse urine samples were quan-
tiﬁed by high-performance liquid chromatography (HPLC)
[reversed-phase C18 column (Atlantis C18, 4.6 · 150 mm;
Waters Associates Inc.), Waters 2695 Separation Module
(Waters Associates Inc.), Waters 996 Photodiode Array
Detector (Waters Associates Inc.)]. Using an isocratic elution
system of 0.1% TFA in water/acetonitrile (98:2 v/v) at a ﬂow
rate of 1 ml/min, the retention time of 6HNic was 7.1 min. The
chromatograms were analyzed at 230 and 295 nm using
Waters Empower  software. 6HNic concentrations in each
sample were determined based on a peak area calibration
curve generated using pure 6HNic.
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6HNic (InterBioScreen, Moscow, Russia) was prepared as a
stock solution of 100 mg/ml in water and used at indicated
ﬁnal concentrations.
RESULTS
Design of the 6-hydroxy-nicotine-responsive
mammalian transgene regulation system
Capitalizing on machinery enabling A.nicotinovorans pAO1
to metabolize nicotine, we have designed a system called
NICE. NICE-controlled transgene modulation in mammalian
cells required two functionally crosstalking components:
(i) an artiﬁcial transactivator (NT1) engineered by fusing
A.nicotinovorans pAO1’s 6-hydroxy-D-nicotine oxidase
gene (6HDNO) repressor HdnoR to the generic H.simplex
type 1 (HSV-1) VP16 transactivation domain (1,38)
(pLM82; PSV40-NT1-pA, NT1, HdnoR-VP16) and (ii) a chi-
meric promoter (PNIC) assembled by cloning 6HDNO-speciﬁc
operator modules (ONIC) adjacent to a minimal version of the
human cytomegalovirus immediate early promoter (PhCMVmin;
PNIC,O NIC-PhCMVmin) (1,39). Following cotransfection of
pLM82 (PSV40-NT1-pA) and pLM83 (PNIC1a-SEAP-pA;
PNIC1a,O NIC-0bp-PhCMVmin), enabling PNIC1a-driven human
placental SEAP expression, into CHO-K1 grown in the
absence of 6HNic, NT1 bound PNIC1a via HdnoR-ONIC inter-
action and initiated high-level SEAP production (48.0 –
7.3 U/l). Akin to 6HNic-mediated derepression of 6HDNO
in A.nicotinovorans pAO1 NT1 adopts a binding-incompetent
allosteric conformation in the presence of 6HNic, which res-
ults in disruption of the NT1-PNIC1a interaction and shutdown
of SEAP production (1.3 – 0.2 U/l) (Figure 1).
6HNic-responsive promoter configurations I—PNIC
containing a single NT1-specific operator
Efﬁcient transcription-initiation of regulated promoters
requires optimal crosstalk between the transcription
machinery, the transactivator tethered to the cognate operator
and the minimal promoter. The distance and twist between the
operator module and the minimal promoter represent spatio-
steric constraints for the assembly of the transcription-
initiation complex and so inﬂuence overall performance of
regulated promoters (40–46). With the aim of designing
optimal PNIC conﬁgurations, we engineered linkers of 2 bp
increments ranging from 0 to 10 bp between ONIC
and PhCMVmin (PNIC1a,O NIC-0bp-PhCMVmin;P NIC1b,O NIC-
2bp-PhCMVmin;P NIC1c,O NIC-4bp-PhCMVmin;P NIC1d,
ONIC-6bp-PhCMVmin;P NIC1e,O NIC-8bp-PhCMVmin;P NIC1f,
ONIC-10bp-PhCMVmin). PNIC1a-f-driven SEAP expression
units (PNIC1a, pLM83; PNIC1b, pLM104; PNIC1c, pLM105;
PNIC1d, pLM106; PNIC1e, pLM107; PNIC1f, pLM108) were
cotransfected with the NT1 expression vector pLM82
(PSV40-NT1-pA) into CHO-K1 and cultivated for 48 h in
the presence (50 mg/ml 6HNic) and absence of 6HNic before
SEAP production was quantiﬁed. The PSV40-driven SEAP
expression used as the control indicated that 6HNic showed
no negative impact on host cell physiology at regulation-
effective concentrations (Figure 2A). PNIC1b harboring 2 bp
between ONIC and PhCMVmin showed the tightest repression of
all promoter conﬁgurations while its maximum SEAP expres-
sion levels compared favorably with PSV40. Although PNIC1e
and PNIC1f promoted higher SEAP production compared with
PNIC1b, their leaky expression was increased as well. Direct
comparison oftheisogenicpromotersPNIC1aandPNIC1f,which
harbor ONIC and PhCMVmin on the same face of the DNA but at
different distances, suggested a distance-dependent increase of
both maximum as well as leaky expression (Figure 2A).
In order to assess the dose-response characteristics of the
NICE technology, CHO-K1 were cotransfected with pLM104
(PNIC1b-SEAP-pA) and pLM82 (PSV40-NT1-pA) and cultiv-
ated for 48 h in the presence of increasing 6HNic concentra-
tions prior to SEAP production proﬁling. SEAP production
gradually decreased at and beyond 50 ng/ml 6HNic until trans-
gene expression was fully repressed at 50 mg/ml 6HNic. Con-
trol conﬁgurations including PSV40-driven SEAP expression
PhCMVmin goi pA ONIC
T
–6 HNic + 6HNic
6HNic
T
PhCMVmin goi pA ONIC
PNIC
NT
NT
Figure 1. Schematic representation of key components of the 6HNic (6HNic)-responsive transgene regulation system (NICE). As a binary transcription-control
system, NICE consists of an artificial 6HNic-dependent transactivator (NT), assembled by fusing the A.nicotinovorans pAO1 6HNic oxidase repressor HdnoR to
functional mammalian transactivation domains (T; e.g. H.simplex VP16, p65 of human NF-kB, a domain of human E2F4) and a chimeric promoter engineered by
placingHdnoR-specificoperatormodules(ONIC)adjacenttoaminimalversionofthehumancytomegalovirusimmediateearlypromoter(PhCMVmin).Intheabsence
of 6HNic ( 6HNic), NT binds to PNIC via direct HdnoR-ONIC interaction and induces PhCMVmin-mediated transcription of the gene of interest (goi). However,
6HNic modifies NT’s allostery such that it is no longer able to bind and induce PNIC, which results in complete transgene repression.
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absence and presence of 100 mg/ml 6HNic conﬁrming that this
nicotine derivative exhibits no deleterious physiologic effects
on mammalian cells at regulation-effective concentrations
(Figure 2B).
6HNic-responsive promoter configurations II—PNIC
containing a tandem NT1-specific operator
In order to increase the expression performance of PNIC1b,w e
cloned a second ONIC (ONIC2) module 50 of ONIC1.P NIC2
derivatives contain a ﬁrst NT1 operator (ONIC1) at an optimal
distance 50 of PhCMVmin and a second operator (ONIC2) placed
0/2/4/6/8/10 bp upstream of ONIC1 (PNIC2,O NIC2-spacer-
ONIC1-NheI-SbfI-4bp-PhCMVmin). Resulting promoters
(PNIC2a,O NIC2-0bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2b,
ONIC2-2bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2c,O NIC2-
4bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2d,O NIC2-6bp-
ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2e,O NIC2-8bp-ONIC1-
NheI-SbfI-4bp-PhCMVmin;P NIC2f,O NIC2-10bp-ONIC1-NheI-
SbfI-4bp-PhCMVmin) were conﬁgured for SEAP expression
(pLM135, PNIC2a-SEAP-pA; pLM136, PNIC2b-SEAP-pA;
pLM137, PNIC2c-SEAP-pA; pLM138, PNIC2d-SEAP-pA;
pLM139, PNIC2e-SEAP-pA; pLM140, PNIC2f-SEAP-pA) and
cotransfected with the NT1 expression vector pLM82 (PSV40-
NT1-pA) into CHO-K1. Transfected cell populations were
grown for 48 h in the presence (50 mg/ml) and absence of
6HNic prior to SEAP quantiﬁcation (Figure 3). Tandem ONIC-
containing modules doubled maximum SEAP expression
levels compared with mono-ONIC PNIC1 promoter derivatives.
However, leaky transcription in the presence of 6HNic was
also increased, which compromised overall regulation per-
formance. PNIC2d, containing 6 bp between the two ONIC mod-
ules supported optimal tightness among 2-ONIC-containing
promoters while transgene expression reached 2-fold higher
levels compared with PNIC1b (Figures 2 and 3). Direct correla-
tion between the number of tandem operator modules and
maximum expression levels is a common observation for tran-
scription control modalities of the NICE type. Also, a qualit-
ative correlation between maximum and leaky expression is
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Figure 2. Regulation performance and adjustability of 6HNic-responsive
promoters (PNIC1) containing a single 6HNic-dependent transactivator (NT)-
specific operator module.(A) 6HNic-responsive promoters containing a single
operator module (ONIC) were engineered to contain linkers of 2 bp increments
ranging from 0 to 10 bp between ONIC and the minimal promoter PhCMVmin
(PNIC1a,O NIC-0bp-PhCMVmin;P NIC1b,O NIC-2bp-PhCMVmin;P NIC1c,O NIC-4bp-
PhCMVmin;P NIC1d,O NIC-6bp-PhCMVmin;P NIC1e,O NIC-8bp-PhCMVmin;P NIC1f,
ONIC-10bp-PhCMVmin). PNIC1a-f-driven SEAP expression units (PNIC1a-SEAP-
pA [pLM83]; PNIC1b-SEAP-pA [pLM104]; PNIC1c-SEAP-pA [pLM105];
PNIC1d-SEAP-pA [pLM106]; PNIC1e-SEAP-pA [pLM107]; PNIC1f-SEAP-pA
[pLM108]) were cotransfected with the NT1 expression vector pLM82
(PSV40-NT1-pA; NT1, HdnoR-VP16) into CHO-K1 and cultivated for 48 h
in the presence (50 mg/ml 6HNic) and absence of 6HNic before SEAP produc-
tion was quantified. SEAP production was compared with pSEAP2-Control-
transfected CHO-K1 cells harboring a glycoprotein expression unit driven by
the SV40 promoter (PSV40). (B) CHO-K1 transfected with pLM82 (PSV40-
NT1-pA) and pLM104 (PNIC1b-SEAP-pA) were cultivated for 48 h in the
presence of increasing 6HNic concentrations, which resulted in adjustable
repressionofthemodelproductproteinSEAP.(Thelinewasaddedforclarity.)
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Figure 3. Regulation performance of 6HNic-responsive promoters (PNIC2)
containing a twin 6HNic-dependent transactivator (NT)-specific operator
module (ONIC1 and ONIC2). Whereas the distance of the most proximal ONIC1
to the minimal version of the human cytomegalovirus promoter (PhCMVmin)
was kept constant, the spacing between ONIC2 and ONIC1 was increased by
2 bp increments (PNIC2a,O NIC2-0bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2b,
ONIC2-2bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2c,O NIC2-4bp-ONIC1-NheI-
SbfI-4bp-PhCMVmin;P NIC2d,O NIC2-6bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;
PNIC2e,O NIC2-8bp-ONIC1-NheI-SbfI-4bp-PhCMVmin;P NIC2f,O NIC2-10bp-
ONIC1-NheI-SbfI-4bp-PhCMVmin). PNIC2a-f-driven SEAP expression units
(PNIC2a-SEAP-pA [pLM135]; PNIC2b-SEAP-pA [pLM136]; PNIC2c-SEAP-pA
[pLM137]; PNIC2d-SEAP-pA [pLM138]; PNIC2e-SEAP-pA [pLM139]; PNIC2f-
SEAP-pA [pLM140]) were cotransfected with the NT1 expression vector
pLM82 (PSV40-NT1-pA; NT1, HdnoR-VP16) into CHO-K1 and cultivated
for 48 h in the presence (50 mg/ml 6HNic) and absence of 6HNic before SEAP
production was quantified. SEAP production was compared with pSEAP2-
Control-transfected CHO-K1 cells harboring a glycoprotein expression unit
driven by the constitutive SV40 promoter (PSV40).
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offer a wide portfolio of transgene regulation performance and
provide a choice of speciﬁc expression/regulation character-
istics, depending on the gene regulation system’s mission.
Engineering of different 6HNic-dependent
transactivators
In addition to rigorous engineering of 6HNic-responsive
promoters, we designed 6HNic-dependent transactivators con-
taining alternative transactivation domains. We selected the
potent transactivation domains of NF-kB (p65) and E2F4
(E2F4), which showed efﬁcient transactivation in antibiotic-
adjustable transgene regulation settings (47–51). VP16 of NT1
was replaced by p65 and E2F4 transactivation domains, which
resulted in NT2 (HdnoR-p65) and NT3 (HdnoR-E2F4),
respectively. The relative transactivation properties of NT1,
NT2 and NT3 were assessed by cotransfection of either
pLM82 (PSV40-NT1-pA), pLM101 (PSV40-NT2-pA) or
pLM102 (PSV40-NT3-pA) and pLM104 (PNIC1b-SEAP-pA)
into CHO-K1 followed by cultivation for 48 h in the presence
and absence of 6HNic and SEAP quantiﬁcation (Figure 4).
Although all transactivators mediated comparable basal
expression levels, their maximum transgene production levels
differed signiﬁcantly. NT2’s transactivation efﬁciency
was lower compared with NT1 but higher than NT3.
Thus, 6HNic-dependent transactivators showed graded
transcription-initiation capacity and provided a choice of dif-
ferent expression windows.
Development of 6HNic-adjustable lentivectors
In order to enable straightforward one-step engineering of
mammalian cells for NICE-controlled transgene expression,
we have designed a set of HIV-1-derived self-inactivating
lentiviral expression vectors exempliﬁed by pLM141
(50LTR-y
+-oriSV40-PPT-RRE-PNIC2d-SEAP-30LTRDU3) and
pLM103(50LTR-y
+-oriSV40-PPT-RRE-PhEF1a-NT1-30LTRDU3).
Cotransduction of pLM141- and pLM103-derived lentiviral
particles into CHO-K1 followed by cultivation of engineered
cell populations at increasing 6HNic concentrations resulted
in precise dose-dependent SEAP expression ﬁne-tuning
(Figure 5A). Besides excellent adjustability, NICE-controlled
SEAP production was fully reversible when followed over a
1 week period of 6HNic addition and removal alternating
every 48 h. SEAP accumulation kinetics, maximum expres-
sion levels in the absence and basal expression levels in the
presence of 50 mg/ml 6HNic remained reproducible following
consecutive expression status switches (Figure 5B). Repeated
ON–OFF or OFF–ON expression switching did neither com-
promise maximum nor basal expression levels.
In parallel, we studied the impact of repressed or induced
expression status imprinting on follow-up expression scen-
arios. CHO-K1 transduced for NICE-controlled SEAP expres-
sion were setfor48htohigh(0, 6HNic)orbasal(1,+6HNic)
glycoprotein production, which was either maintained or
switched twice during subsequent 48 h cultivation periods
(48 h!48 h!48 h; 0!0!0, 0!0!1, 0!1!0,
0!1!1, 1!0!0, 1!0!1, 1!1!0, 1!1!1).
Irrespective of the cell population’s previous NICE-
controlled expression history, SEAP production levels in the
presenceorabsenceof6HNicremainedconsistent(Figure5C).
Lentiviral implementation of NICE-controlled ﬁne-tuning of
transgene expression enabled stable, adjustable and reversible
regulation characteristics as well as sustained regulation
kinetics for over 6 days.
In vivo validation of NICE-adjustable transgene
expression in mice and chicken embryos
For in vivo validation of NICE-adjustable transgene expres-
sion, we implanted microencapsulated CHO-K1 cells trans-
genic for NICE-controlled SEAP expression into coherent
alginate-poly-L-lysine-alginate capsules intraperitoneally into
mice (200 cells/capsule). Treated mice were exposed to
different daily 6HNic doses, and serum SEAP levels were
quantiﬁed 72 h after implantation. While NICE-induced
SEAP production resulted in high-level concentrations of this
glycoprotein in the serum of treated mice (106 – 21 mU/l),
6HNic was unable to repress heterologous production even at
concentrations of 100 mg/kg. 6HNic is a unique unphysiologic
compound, which may fail to control NICE-driven gene
expression due to unknown in vivo derivatization/degradation
or rapid clearance from the body. Indeed, HPLC-based ana-
lysis of urine samples collected from 6HNic-treated mice
showed that 90% of the administered nicotine derivative
was excreted after 2 h (Figure 6). Therefore, further efforts
will be required to establish NICE technology in mammals.
However, the 6HNic concentration administered to mice
without signiﬁcant side effects remains impressive and holds
promises for future applications.
In order to alleviate possible 6HNic clearance, we
cotransduced chicken embryoswith lentiviral particles derived
from pLM103- (50LTR-y
+-oriSV40-cPPT-RRE-PhEF1a-NT1-
30LTRDU3) and pLM146- (50LTR-y
+-oriSV40-cPPT-RRE-
PNIC3-VEGF121-30LTRDU3). The pLM146 lentivector harbors
aP NIC3 (ONIC-4bp-NheI-SbfI-PhCMVmin)-driven human
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Figure 4. Regulation performance of different 6HNic-dependent transactiva-
tors. A.nicotinovorans pAO1’s 6HNic oxidase repressor HdnoR was fused to
differenttransactivationdomainsderivedfrom(i)H.simplexvirus(VP16;NT1,
HdnoR-VP16), (ii) human NF-kB (p65; NT2, HdnoR-p65) and (iii) human
E2F4 (E2F4; NT3, HdnoR-E2F4). The regulation performance of NT1, NT2
and NT3 was assessed by cotransfection of either pLM82 (PSV40-NT1-pA),
pLM101 (PSV40-NT2-pA) or pLM102 (PSV40-NT3-pA) and pLM104 (PNIC1b-
SEAP-pA) into CHO-K1 followed by cultivation for 48 h in the presence and
absence of 6HNic and SEAP quantification. SEAP production was compared
with pSEAP2-Control-transfected CHO-K1 cells harboring a glycoprotein
expression unit driven by the constitutive SV40 promoter (PSV40).
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embryo’s vascularization in a 6HNic-adjustable manner
(Figure 7). Cotransduction of these lentiviral particles into
CHO-K1 followed by cultivation of infected cell populations
at increasing 6HNic concentrations resulted in tight dose-
dependent VEGF121 expression ﬁne-tuning (Figure 8). Micro-
scopic analysis of VEGF121-mediated neovascularization, as
well as vessel morphology in the CAM of chicken embryos
grown for 3 days at decreasing 6HNic concentrations or
6HNic-free conditions (50, 1, 0.1, 0 mg/ml, see Figure 7)
showed a dose-dependent angiogenic response characterized
by a general increase in blood vessel number, atypical (brush-
and delta-like) endpoint patterns, irregular tortuous vessel
shape and multiple vessel branching. All of those effects
could be completely repressed by treating the chicken embryo
with 50 mg/ml 6HNic. VEGF121-induced impact on vessel
structure was conﬁned to a 4 mm radius around the site of
lentiviral particle application and could not be observed on the
same CAM beyond this perimeter (Figure 7). These results
conﬁrm 6HNic-adjustable transgene transduction in vivo.
DISCUSSION
Long appreciated in basic sciences for their power to reveal
gene-function correlations, heterologous transgene control
systems have gathered momentum and now stand on the eve
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Currently available transcription control modalities capitalize
on the generic design principle of the pioneering TET system:
(i) clinically licensed tetracycline as inducer, (ii) bacterial
repressor fused to mammalian cell-compatible transactivation
domain as transactivator and (iii) transactivator-speciﬁc
promoter assembled by fusing transactivator-speciﬁc operator
modules to a minimal eukaryotic promoter. Besides their
relationship to the TET conﬁguration alternative trans-
gene control systems differ signiﬁcantly in the regulating
small molecule (clinically licensed small-molecule drugs
[antibiotics (7,9–11), immunosuppressive agents, (12), hor-
mones and hormone agonists, (13–15), type-2 diabetes drug,
(19,53), clinically inert compounds (17,18), temperature (16)
and gaseous acetaldehyde (20)]), the origin of the trans-
activator [prokaryotic origin (7,9–11,16–18,20) (http://www.
qbiogene.com/products/gene-expression/qmateslideshow/index.
htm), mammalian origin (13,14,19,53)] and their promoter
conﬁgurations [tandem operator modules, minimal promoter
origin, relative promoter-operator spacing; see (40) as well as
(52) for a non-limiting overview]. Despite the portfolio of
different transgene regulation systems, there is nothing like
the best control modality. All systems are associated with pros
and cons:
(i) clinicallylicensedinducersareintuitivelybettersuitedfor
therapeutic applications, although ongoing administration
of small-molecule drugs is prone to side effects,
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Figure 7. In vivo microscopy of angiogenic response in the CAM of 12-day-old chicken embryos 72 h post cotransduction with lentiviral particles derived from
pLM103- (50LTR-y
+-oriSV40-cPPT-RRE-PhEF1a-NT1-30LTRDU3) and pLM146- (50LTR-y
+-oriSV40-cPPT-RRE-PNIC3-VEGF121-30LTRDU3). Following adminis-
tration of 50 mg/ml 6HNic 1 h post transduction, NICE-controlled VEGF121 production was completely repressed (A) and microvascular growth compared with
mock-transduced 6HNic-treated control embryos (B). Transduced cultures treated with decreasing 6HNic concentrations showed an increasing dose-dependent
angiogenicresponsewithatypical(brush-anddelta-like)endpointpatterns(arrows)andirregulartortuousvesselshape(arrowhead)withinaperimeterof4mmofthe
transductionsite(dashedcircle).[(C)1mg/ml6HNic;(D)0.1mg/ml6HNic;(E)no6HNic;seeFigure8forVEGF121expressionprofiles.](F)Detailrepresentationof
the red-framed part of D.
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operate in the absence of pleiotropies, yet may elicit
immune responses,
(iii) eukaryotic-derived promoter-transactivator systems are
compatible with the immune system, yet may interfere
with endogenous regulatory networks.
The demands for transgene control modalities are as different
as the systems themselves: while the gene therapy and tissue
engineering communities prefer endogenous regulation
systems adjusted by clinically licensed small-molecule
drugs, biopharmaceutical manufacturing representatives
favor heterologous prokaryotic-derived systems ﬁne-tuned
by clinically inert compounds.
Based on the components of A.nicotinovorans pAO1’s
nicotine mobilization machinery, we have designed a novel
gene control system to adjust transgene expression in response
to the water-soluble nicotine derivative 6HNic. The NICE
technology mediated high-level expression, tight repression,
precise expression ﬁne-tuning and reversible transcription
control in the absence of compromising imprinting originating
from previous switching history. All of those performance
characteristics have been conﬁrmed in a variety of expression
conﬁgurations in mammalian cells, by lentivirus-mediated
transduction as well as in chicken embryos. As a closed
system, chicken embryos supported adjustable angiogenic
responses in vivo. However, 6HNic was unable to modulate
SEAP expression in mice, suggesting that its high water
solubility promoted rapid renal clearance and resulted in
control-incompatible pharmacokinetics in whole animals.
Starting with a generic design concept, we have improved
the NICE technology by (i) varying ONIC-PhCMVmin spacing,
(ii) engineering tandem ONIC repeats and modifying the inter-
ONIC distance and by (iii) swapping the transactivation
domains fused to HdnoR. In order to selectively improve
the regulation performance of hybrid NICE promoters,
we focused on optimizing the spatio-steric relation between
promoter, transactivator and transcription-initiation complex.
The importance of rotational alignment of cis-acting elements
on overall promoter performance has been investigated in
several systems. The synthesis of those studies suggested
appropriate helical phasing to be required for optimal pro-
moter activity. Non-limiting examples included the promoter
of the human serine protease B gene (54), the promoter of
the Escherichia coli araBAD operon (55) and the promoter of
the human HLA-DR gene (56). Furthermore, helical period-
icity has been observed for promoter-enhancer crosstalk in
SV40 and HIV-1 viruses (57,58). As for heterologous gene
regulation systems, Weber and co-workers (47) have recently
exempliﬁed that the spacing and torsion angle between the
operator and minimal promoters had dramatic impact on the
overall regulation performance. This observation could be
conﬁrmed for the NICE system. Increasing the ONIC-PhCMVmin
distance by 2 bp increments resulted in a promoter portfolio
with graded response characteristics.
It is commonly accepted that transactivator-mediated tran-
scription-initiation increases with the number of cognate oper-
ator modules (59,60). Similarly, NICE promoters harboring
tandem operator modules showed 2- to 3-fold higher transgene
expression compared with mono ONIC-containing promoters.
The net increase of the maximum expression levels was a
function of the inter-ONIC distance. The relative spacing
between different operator modules has long been recognized
as an essential factor for promoter performance (46,61–65).
For example, analysis of beta interferon (IFN-b) gene activa-
tion showed that deletion,or rearrangement of any one of the
enhancer modules compromises transcription performance
(66). Also, variation of the spacing between individual activ-
ator binding sites within the TCR a enhancer modulated
enhancer activity in a helical phasing-dependent manner
(67). We have modiﬁed the inter-ONIC spacing by 2 bp incre-
ments while leaving the tandem operator-minimal promoter
distance invariant. Optimal spacing resulted in up to 3-fold
increasedmaximum expression levels.However, basal expres-
sion was higher as well.
Since the transactivator interfaces with promoter and
transcription-initiation machinery it has a decisive impact on
the overall regulation and expression performance of trans-
gene control modalities. We have therefore equipped HdnoR
with different viral and human transactivation domains, which
mediated graded response characteristics in CHO-K1.
The NICE optimization studies have resulted in a portfolio
of different 6HNic-responsive promoter/transactivator conﬁg-
urations, which show superior key characteristics including
tight repression and maximum expression levels. The choice
of different promoter/transactivator combinations enables
unmatched adaptation of NICE-controlled transgene expres-
sion to speciﬁc needs: tight repression is best satisﬁed by
mono-ONIC-containing promoters while promoters with tan-
dem ONIC modules support high-level transgene expression.
Our rigorous NICE analysis has exempliﬁed its potential for
sophisticated cell engineering related to basic and applied
research applications.
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